FindTrial
Sign In

Antibody response after COVID 19 vaccine provided along with ayurvedic medicine (NOQ19)

A prospective, double blind, randomized clinical study to evaluate the antibody response after Covid-19 vaccine when provided along with NOQ19,an ayurvedic medicine

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/12/038587
Enrollment
500
Registered
2021-12-13
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Sri Sri Institute of Advance Research SSIAR
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Participants yet to receive Covid-19 vaccine Residence within a 10-kilometre radius of AIIMS hospital

Exclusion criteria

Exclusion criteria: Patients with associated comorbidities like hypertension, type 2 or type 1 diabetes or chronic or acute renal failure or any major systemic illness Patients on Immuno-suppression therapy Pregnant Women or lactating mothers

Design outcomes

Primary

MeasureTime frame
Primary - Change from baseline in count of antibodies following first dose of vaccine, second dose of vaccine Timepoint: 4 times, Baseline, after first dose of vaccine, after second vaccine dose,8 weeks after second dose of vaccine—

Secondary

MeasureTime frame
Any adverse effects, Refusal rates Timepoint: After first vaccine dose, second vaccine dose, 8 weeks after second vaccine dose—

Countries

India

Contacts

Public ContactAnju Dhawan

AIIMS New Delhi

dranjudhawan@gmail.com01126593236

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026